Table 1.
Patient demographics and biochemical tests.
| Characteristics | n = 165 |
|---|---|
| Age, years (mean ± SD) | 53.5 ± 16.1 |
| Gender, male (%) | 96 (58.1%) |
| BMI, kg/m2 (mean ± SD) | 27.4 ± 5.25 |
| AST, IU/L (median, 25th pct–75th pct) | 31 (6–78) |
| ALT, IU/L (median, 25th pct–75th pct) | 30 (10–190) |
| GGT, IU/L (median, 25th pct–75th pct) | 42.5 (20–800) |
| ALP, IU/L (median, 25th pct–75th pct) | 80 (6.7–315) |
| Platelet count, 103/mm3 (median, 25th pct–75th pct) | 182 (25–574) |
| Fibrosis stage (assessed with VCTE) (%) | |
| (F0-F1) | 82 (49.6%) |
| (F2) | 26 (15.7%) |
| (F3) | 11 (6.6%) |
| (F4) | 46 (28.1%) |
| Etiology of chronic liver diseases (%) | |
| Hepatitis B virus (HBV) | 35 (21.2%) |
| Hepatitis C virus (HCV) | 46 (27.9%) |
| Non-alcoholic fatty liver disease (NAFLD) | 31 (18.7%) |
| Alcohol liver disease | 25 (15.2%) |
| Healthy subjects | 28 (17%) |
SD = standard deviation; IQR = interquartile range; BMI = body mass index; AST = aspartate aminotransferase; ALT = alanine aminotransferase; GGT = gamma-glutamyl transferase; ALP = alkaline phosphatase; VCTE = vibration controlled transient elastography.